AU2002213785A1 - A method of analgesia - Google Patents

A method of analgesia

Info

Publication number
AU2002213785A1
AU2002213785A1 AU2002213785A AU1378502A AU2002213785A1 AU 2002213785 A1 AU2002213785 A1 AU 2002213785A1 AU 2002213785 A AU2002213785 A AU 2002213785A AU 1378502 A AU1378502 A AU 1378502A AU 2002213785 A1 AU2002213785 A1 AU 2002213785A1
Authority
AU
Australia
Prior art keywords
pain
tetrodotoxin
cancer
ttx
sodium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213785A
Other languages
English (en)
Inventor
Qingbin Dong
Frank Haykong Shum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wex Medical Ltd
Original Assignee
WEX MEDICAL INSTRUMENTATION CO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WEX MEDICAL INSTRUMENTATION CO filed Critical WEX MEDICAL INSTRUMENTATION CO
Publication of AU2002213785A1 publication Critical patent/AU2002213785A1/en
Assigned to WEX MEDICAL LIMITED reassignment WEX MEDICAL LIMITED Amend patent request/document other than specification (104) Assignors: WEX MEDICAL INSTRUMENTATION CO
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AU2002213785A 2000-09-18 2001-09-11 A method of analgesia Abandoned AU2002213785A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN00124517 2000-09-18
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (1)

Publication Number Publication Date
AU2002213785A1 true AU2002213785A1 (en) 2002-03-26

Family

ID=4590472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213785A Abandoned AU2002213785A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Country Status (26)

Country Link
US (1) US6407088B1 (es)
EP (3) EP2298306B1 (es)
JP (1) JP2004508404A (es)
KR (2) KR100891568B1 (es)
CN (1) CN1284536C (es)
AT (2) ATE447959T1 (es)
AU (1) AU2002213785A1 (es)
BG (1) BG107690A (es)
BR (1) BR0113961A (es)
CA (1) CA2421562C (es)
DE (1) DE60140466D1 (es)
EA (1) EA004870B1 (es)
EE (1) EE200300106A (es)
ES (1) ES2435463T3 (es)
HR (1) HRP20030202A2 (es)
HU (1) HUP0302677A3 (es)
IL (1) IL154342A0 (es)
IS (1) IS6719A (es)
MX (1) MXPA03002389A (es)
NO (1) NO323960B1 (es)
PL (1) PL360616A1 (es)
SK (1) SK3732003A3 (es)
UA (1) UA76960C2 (es)
WO (1) WO2002022129A1 (es)
YU (1) YU17103A (es)
ZA (1) ZA200301852B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526648A (ja) 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
US20030100574A1 (en) 2001-11-15 2003-05-29 Wilson Nestor Antonio Lagos Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
CN1997373B (zh) * 2004-05-07 2010-12-22 菲特托克斯有限公司 藻毒素及其用途
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (en) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
EP1690541A1 (en) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
TW200640463A (en) * 2005-02-11 2006-12-01 Esteve Labor Dr Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1714655A1 (en) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
EP1931349A4 (en) * 2005-08-25 2009-08-05 Wex Pharmaceuticals Inc USE OF SODIUM CHANNEL BLOCKERS TO TREAT MUSCULO-SKELETAL PAIN
EP1928452A4 (en) * 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
EP2394646B1 (en) 2006-03-27 2018-07-25 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844782A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
EP1844783A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (en) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
CN101730467A (zh) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 神经病性疼痛的治疗
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
US9107925B2 (en) 2010-02-10 2015-08-18 Phytotox Limited Sodium channel blocker for treatment of loss of superficial sensitivity
JP2014504184A (ja) 2010-12-01 2014-02-20 スパイナル・モデュレーション・インコーポレイテッド 神経構造への薬剤の直接送達
MX2015010749A (es) 2013-03-14 2015-11-30 Regeneron Pharma Anticuerpos humanos para nav1.7.
CN105142625B (zh) 2013-03-15 2019-09-06 儿童医学中心公司 用于长效局部麻醉的新蛤蚌毒素组合配制品
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
NO20030915D0 (no) 2003-02-27
KR20030034181A (ko) 2003-05-01
YU17103A (sh) 2006-03-03
KR100891568B1 (ko) 2009-04-03
IL154342A0 (en) 2003-09-17
NO20030915L (no) 2003-04-25
UA76960C2 (en) 2006-10-16
IS6719A (is) 2003-02-14
DE60140466D1 (de) 2009-12-24
EP2298306A1 (en) 2011-03-23
BG107690A (bg) 2004-01-30
HUP0302677A3 (en) 2005-01-28
CN1284536C (zh) 2006-11-15
JP2004508404A (ja) 2004-03-18
EP1563839B1 (en) 2012-01-25
NO323960B1 (no) 2007-07-23
HRP20030202A2 (en) 2005-02-28
CA2421562C (en) 2011-05-24
EP2298306B1 (en) 2013-09-11
EP1563839A1 (en) 2005-08-17
EE200300106A (et) 2005-04-15
ATE542534T1 (de) 2012-02-15
PL360616A1 (en) 2004-09-20
HUP0302677A2 (hu) 2003-11-28
ES2435463T3 (es) 2013-12-19
SK3732003A3 (sk) 2005-05-05
EP1320369A1 (en) 2003-06-25
WO2002022129A1 (en) 2002-03-21
MXPA03002389A (es) 2004-03-12
KR20070112864A (ko) 2007-11-27
CA2421562A1 (en) 2002-03-21
ATE447959T1 (de) 2009-11-15
EA004870B1 (ru) 2004-08-26
BR0113961A (pt) 2004-01-13
EP1320369B1 (en) 2009-11-11
ZA200301852B (en) 2004-06-21
US6407088B1 (en) 2002-06-18
CN1356104A (zh) 2002-07-03
EP1320369A4 (en) 2003-07-02
EA200300172A1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
US6407088B1 (en) Method of analgesia
Charney et al. Hypnotics and sedatives
CN108883108A (zh) 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途
AU2022290019A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
JP7265526B2 (ja) てんかん治療剤
AU2007200073B2 (en) A Method of Analgesia
EA008339B1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
CN112569237B (zh) 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
JP2003502376A (ja) 性機能障害および血管収縮に関する疾患の予防および治療におけるイカリンの使用
AU2015363757B2 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
CN115887448B (zh) 一种治疗失眠用组合物
Yadav Pharmacology & Toxicology
Budhiraja Elementary Pharmacology & Toxicology 4e
CN115745890A (zh) 一种酯键化合物及其制备方法和应用、镇痛药物
Iermolenko et al. Pharmacology. Part 1 Medical prescription. General pharmacology. Pharmacology of drugs acting on nervous system: self-study guide for third year medical students
WO2010120203A1 (ru) Применение органических красителей в качестве обезболивающих средств

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted